Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05896267 · ClinicalTrials.gov registry record · NA
SpO2 Data Collection in Pediatric Patients Using INVSENSOR00061
A NA study, sponsored by Masimo Corporation.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT05896267: Completed NA study, sponsored by Masimo Corporation.
NCT05896267 is a NA study that has completed, run by Masimo Corporation. The registered enrollment target is 64 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05896267, a NA study, has completed, sponsored by Masimo Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a prospective, non-randomized data collection study to evaluate the form, fit, and function of INVSENSOR00061.
Primary Outcome
SpO2 accuracy will be determined by calculating the Arithmetic Root Mean Square (ARMs) value which will be reported as percent of oxygen saturated hemoglobin. The noninvasive oxygen saturation measurement (SpO2) from the INVSENSOR00061 will be compared to the noninvasive oxygen saturation measurement (SpO2) value from the RD SET Neo sensor.
Interventions
- DEVICE Masimo INVSENSOR00061
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-05-15 |
| Est. Completion | 2023-06-22 |
| Phase | NA |
What the finished NCT05896267 record still lists
NCT05896267 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Masimo INVSENSOR00061 is the first listed.
NCT05896267 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05896267 about?
NCT05896267 is a clinical study titled "SpO2 Data Collection in Pediatric Patients Using INVSENSOR00061". This is a prospective, non-randomized data collection study to evaluate the form, fit, and function of INVSENSOR00061.
What is the current status of trial NCT05896267?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2023-05-15. Estimated completion is 2023-06-22.
What interventions are being tested in trial NCT05896267?
The interventions under investigation include: Masimo INVSENSOR00061 (DEVICE).
Who is sponsoring clinical trial NCT05896267?
This trial is sponsored by Masimo Corporation, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05896267's enrollment target sits among peer trials
64 1147th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI